Demyelinating Diseases Treatment: How Relapse Control and Long-Term Monitoring Are Planned

The first sign was a smudge. Reading a text message, a 31-year-old teacher noticed the letters on her left side had gone soft, as if someone had breathed on the screen. Two days later the eye ached when she looked sideways. A week after that she was sitting in a neurology clinic, hearing the word demyelinating for the first time and wondering what it would mean for the rest of her life.

Understanding how demyelinating diseases are treated turns out to be less frightening than the word itself. The care plan is built in layers: calming the attack that is happening now, lowering the odds of the next one, and keeping watch over months and years so nothing slips past unnoticed.

This explainer walks through each layer as a neurology team would describe it in clinic: what actually happens inside the nerve, what the medicines are trying to do, and why so much of good care is patient, unhurried monitoring.

How demyelinating diseases are treated: the three layers of care

Ask a neurologist how demyelinating diseases are treated and you will usually hear about three jobs that run at different speeds. The first is urgent: settle the current attack. The second is strategic: reduce how often attacks happen and how much damage they leave behind. The third is continuous: manage symptoms, protect general health and watch for change.

The urgent job is handled with a short course of corticosteroids, medicines that dampen inflammation quickly. For severe attacks that do not respond, plasma exchange may be used; this filters antibodies and other immune proteins out of the blood. The NHS notes that steroids can shorten a relapse but do not change the long-term course of the disease, which is why the second layer exists.

That second layer is made of disease-modifying therapies, a broad family of medicines that alter how the immune system behaves so it is less likely to attack myelin again. They are taken or given over years, not days, and they are chosen to match the specific condition, its activity level and the person’s circumstances.

The third layer is easy to underrate because it is not dramatic. Fatigue, stiffness, bladder changes, pain and low mood are often what shape daily life more than relapses do, and each has its own treatment pathway, from physiotherapy to targeted medicines to counseling.

Running through all three is monitoring: neurological examinations, MRI scans of the brain and spinal cord, and blood tests that check both disease activity and medicine safety. None of these layers works well in isolation, and the sequence and intensity are set by the treating team rather than by any fixed rule.

What actually happens to a nerve when myelin is damaged

Myelin is the fatty insulation wrapped around nerve fibers, much like the plastic coating on an electrical cable. Its job is speed. A well-insulated fiber carries a signal in a series of quick jumps; strip the coating and the signal slows, scatters or stops altogether.

In a demyelinating disease, immune cells that normally fight infection mistake myelin for a threat. They cross into the brain, optic nerves or spinal cord, release inflammatory chemicals and damage the sheath in patches. On an MRI scan these patches show up as lesions, small areas of altered tissue. What a person feels depends entirely on where the patch sits: on the optic nerve it blurs vision, in the spinal cord it may cause numbness or weakness, in the brainstem it can bring double vision or dizziness.

The body is not passive. Specialized cells called oligodendrocytes can lay down new myelin, a process called remyelination, and this is one reason many people recover partly or fully after an attack. The NIH’s National Institute of Neurological Disorders and Stroke describes how repair is often incomplete, and repeated inflammation can eventually injure the nerve fiber itself, not just its coating. That fiber damage is what tends to drive lasting disability.

This mechanism explains the whole treatment logic. Anti-inflammatory medicines act fast because they quiet the immune assault while it is underway. Disease-modifying therapies act slowly because they change immune behavior over time. And there is currently no approved medicine that reliably rebuilds myelin on demand, although remyelination is an active research area. Treatments described as regrowing myelin remain experimental and are not yet standard care.

Which conditions count as demyelinating diseases?

Demyelinating disease is a category, not a single diagnosis, and the treatment plan changes markedly depending on which member of the family is involved. Getting the label right is therefore the first treatment decision.

Multiple sclerosis (MS) is the most common, according to Mayo Clinic, and most of what is written about demyelination refers to it. Neuromyelitis optica spectrum disorder (NMOSD) mainly affects the optic nerves and spinal cord and is often linked to an antibody against a water-channel protein called aquaporin-4. MOG antibody-associated disease (MOGAD) is a newer diagnosis defined by a different antibody. Acute disseminated encephalomyelitis (ADEM) is typically a single, widespread attack, more common in children, often following an infection.

Optic neuritis and transverse myelitis are names for inflammation in one place, the optic nerve or a segment of spinal cord. They may occur once and never return, or they may be the first sign of one of the conditions above.

Demyelination can also affect the peripheral nerves, those outside the brain and spinal cord. Guillain-Barré syndrome is a rapid-onset example; chronic inflammatory demyelinating polyneuropathy (CIDP) is its slower cousin. These are treated with immune therapies such as intravenous immunoglobulin or plasma exchange rather than with MS disease-modifying drugs.

Why does the distinction matter so much? Some medicines that reduce relapses in MS appear ineffective or even harmful in NMOSD, so a person with recurrent optic neuritis needs antibody testing before a long-term treatment is chosen. Blood tests, spinal fluid analysis and the pattern of lesions on MRI are all used to separate these conditions, and this sorting is done by the neurology team before any preventive therapy begins.

What triggers demyelination in the first place?

People often arrive at clinic convinced they did something to bring this on. The honest answer is that no single trigger has been proven, and most of the identified factors nudge risk rather than cause disease outright.

Immune-mediated demyelination sits on a foundation of genetic susceptibility. Having a close relative with MS raises the odds, though most people with MS have no affected relative, as Mayo Clinic explains. Certain viral infections are strongly associated; the Epstein-Barr virus, which causes glandular fever, has the most consistent link. Low vitamin D and limited sunlight exposure are associated with higher risk, and smoking is linked both to developing MS and to faster progression. Obesity in adolescence has also been associated with higher risk in observational studies.

Other forms of demyelination have clearer causes. ADEM frequently follows a viral illness or, rarely, a vaccination. Some demyelination is not immune-driven at all: severe vitamin B12 deficiency, certain toxins, and a rapid correction of very low blood sodium can each injure myelin through different mechanisms. This is why a first demyelinating episode prompts blood tests that look well beyond autoimmunity.

Relapse triggers, meaning what sets off a new attack in someone already diagnosed, are a separate question. Infections, particularly urinary and respiratory ones, are associated with a higher chance of relapse in the following weeks. Stress is often blamed, and research findings are mixed; the evidence is suggestive but not conclusive. Heat can temporarily worsen existing symptoms without causing new damage, a distinction that matters when someone feels worse on a hot afternoon.

What the evidence does not support is the idea that diet alone, a specific food, or a single stressful event causes demyelination. Risk is cumulative and probabilistic, not a matter of blame.

How demyelinating diseases are treated when a relapse strikes

A relapse, also called a flare or exacerbation, is defined as new or worsening neurological symptoms lasting at least 24 hours in the absence of fever or infection. The NHS uses this threshold because short-lived flickers of symptoms, lasting minutes or hours, are common and usually reflect temporary conduction changes in old lesions rather than new inflammation.

The first step is confirmation. A clinician will check for infection, since a bladder infection can mimic a relapse by amplifying existing symptoms, a phenomenon sometimes called a pseudo-relapse. Treating the infection often settles the symptoms without any steroid at all.

If a true relapse is confirmed and the symptoms are disabling, high-strength corticosteroids are the standard treatment. They work by suppressing the inflammatory cascade within the lesion, reducing swelling and allowing signals to pass again. They are given as a short course, either intravenously or by mouth, and the choice depends on severity and local practice. Mild relapses, such as a small patch of numbness, are often left to recover on their own, because steroids carry side effects, including mood changes, sleep disturbance, raised blood sugar and stomach irritation, and the NHS advises against frequent courses.

For severe relapses that do not improve with steroids, plasma exchange may be offered. Blood is drawn, the liquid portion containing antibodies is removed and replaced, and the blood is returned. In NMOSD, where antibodies drive the attack, plasma exchange is often considered early.

Recovery after a relapse can take weeks or months, according to the NHS, and steroids speed the early phase rather than change the final outcome. That is a point worth sitting with: the medicine that feels most powerful in the moment is the one that does least for the long run.

How disease-modifying therapies work to prevent future relapses

Disease-modifying therapies (DMTs) are medicines that alter the immune system’s behavior so it is less inclined to attack myelin. They do not repair existing damage and they do not treat symptoms directly. Their purpose is to lower the frequency of relapses and slow the build-up of new lesions on MRI.

They work through several distinct mechanisms. Some, such as interferon beta and glatiramer acetate, shift the immune system toward a less inflammatory state through pathways that are still only partly understood. Fumarate medicines appear to act on inflammatory signaling and oxidative stress. S1P receptor modulators trap certain white blood cells in lymph nodes so fewer reach the brain. Natalizumab blocks the molecular doorway that immune cells use to cross from blood into the central nervous system. Anti-CD20 monoclonal antibodies deplete B cells, a type of white blood cell now understood to be central to MS inflammation. Cladribine and alemtuzumab reduce lymphocyte numbers for an extended period after short treatment courses.

Each mechanism carries a characteristic safety profile. Blocking immune cell entry to the brain, for instance, is associated with a rare brain infection called progressive multifocal leukoencephalopathy, which is why blood tests for the JC virus are part of monitoring on that class, as Mayo Clinic describes. B-cell depletion can lower antibody levels over time and increase infection risk.

Timelines are slow by design. Most DMTs take weeks to months to reach their full effect, and their benefit is judged over years using relapse counts and MRI, not over days.

For NMOSD, different targets are used: complement inhibitors, IL-6 receptor blockers and anti-CD19 antibodies. For CIDP, immunoglobulin or immune-suppressing medicines are typical. Which medicine, if any, and when to change it, are decisions for the prescribing neurologist based on the individual’s disease activity, other health conditions, pregnancy plans and preferences.

Who is usually offered preventive treatment, and who is asked to wait

Not everyone with a demyelinating episode is started on a long-term therapy, and the reasons are more nuanced than caution alone.

People with relapsing-remitting MS who have had recent relapses or show new activity on MRI are usually offered a DMT, and modern guidelines, including those summarized by the NHS, favor starting relatively early because relapses in the first years are thought to shape long-term outcome. A person whose MRI shows many lesions, or who recovered incompletely from an attack, is often considered for one of the higher-efficacy classes from the outset. Someone with NMOSD is typically started on preventive treatment after a first confirmed attack, because relapses in that condition tend to be severe.

Others are asked to wait, or to monitor rather than treat. A single episode of optic neuritis with a normal brain MRI and negative antibodies may never recur, and some clinicians follow such a person with repeat scans before committing to years of medicine. A person with ADEM has usually had one attack and needs observation rather than preventive therapy. In primary progressive MS, where disability accrues without clear relapses, fewer DMTs have shown benefit, and eligibility is narrower.

Individual circumstances weigh heavily. Someone planning pregnancy may defer or choose a medicine considered compatible with that plan. Active infections, certain cancers, very low white blood cell counts or a history of specific viral exposures can rule out particular classes. Age and frailty shift the balance too; the immune system becomes less inflammatory with age, and the infection risks of strong immunosuppression rise.

Waiting is not the same as doing nothing. It usually means scheduled MRI, a clear plan for what would prompt treatment, and an open channel to report new symptoms. The threshold for acting is set jointly, and it can be revisited at every review.

How long-term monitoring is planned: MRI, blood tests and reviews

Monitoring is where good care becomes visible over years. It has two purposes that are easy to blur: tracking the disease, and tracking the safety of the medicine used against it.

Disease tracking rests on the neurological examination and MRI. A baseline scan is taken before or shortly after a therapy starts, so that later scans have something to compare against; without it, an early lesion can be mistaken for treatment failure. Follow-up scans then look for new or enlarging lesions and for areas of active inflammation that light up with contrast dye. A new lesion on a person taking a DMT is a signal to the team, not necessarily a reason to switch, but a prompt to reassess.

Safety tracking is medicine-specific. Some DMTs need regular blood counts and liver tests, others need heart rhythm checks when first started, and some need specific antibody tests. Cleveland Clinic and Mayo Clinic both describe how the monitoring schedule is tied to the mechanism of the chosen drug.

What is monitored	Why	Typical tools
Relapses and symptoms	Judge whether the disease is controlled	Clinic review, symptom diary
Brain and spinal cord lesions	Detect silent activity before symptoms	MRI with and without contrast
Blood counts and organ function	Catch medicine side effects early	Routine blood tests
Infection risk markers	Screen for specific risks linked to a drug class	Targeted antibody or viral tests
Function and wellbeing	Guide rehabilitation and support	Walking, hand and cognition assessments, mood screening

The rhythm of all this, how often scans and tests are repeated, is set by the neurology team for each individual and adjusted as circumstances change. Frequent early checks often give way to longer intervals once a treatment appears stable and well tolerated.

What the first weeks after a relapse usually look like

The days after a relapse tend to follow a recognizable arc, even though the details vary with where the lesion sits.

In the first few days, if steroids are given, many people notice that inflammation-related symptoms begin to ease, though some feel jittery, sleepless or unusually hungry from the medicine itself. A metallic taste and facial flushing are common during intravenous courses. Blood sugar can rise temporarily, which matters most for people with diabetes. These effects fade as the course ends.

Over the following weeks, recovery continues under its own power. Signals begin to pass through the damaged area again as swelling settles and some remyelination occurs. Vision after optic neuritis, for example, usually improves over weeks to months, according to the NHS, though color perception may lag or remain subtly altered. Fatigue is often heavy during this window, and the temptation to push back into a full routine can be counterproductive.

Rehabilitation frequently starts in this phase. A physiotherapist may work on balance or gait if the legs were affected; an occupational therapist may suggest ways to manage hand weakness or energy budgeting at work. Early rehabilitation is about relearning efficient movement while the nervous system is adapting, not about forcing strength.

The team will usually arrange a follow-up review, and often an MRI, to confirm the relapse has settled and to see whether it signals a need to start or change preventive therapy. A relapse on treatment is not a failure of the person; it is data.

Emotionally, this period can be harder than the acute phase. Uncertainty about recovery, disruption to work and worry about the future are normal, and neurology teams generally regard psychological support as part of relapse care rather than an optional extra.

Demyelinating disease symptoms and treatment beyond relapses

Between attacks, and in progressive forms where attacks are rare, day-to-day symptoms carry the real weight. Each has a pathway, and most respond better to a combination of approaches than to a single pill.

Fatigue is the symptom people most often name as the hardest. It is not ordinary tiredness; it can arrive mid-morning after a full night’s sleep. Management starts with excluding contributors such as poor sleep, low mood, anemia or thyroid problems, then moves to energy conservation techniques, graded exercise and, in some cases, medicines that a neurologist may consider. Regular aerobic and resistance exercise has consistent support in the evidence summarized by Johns Hopkins and Cleveland Clinic, both for fatigue and for mobility.

Spasticity, stiffness caused by overactive nerve signals to muscles, is treated with stretching, physiotherapy and muscle-relaxant classes when needed; focal injections may be used for a single tight muscle group. Nerve pain, which can feel burning or electric, tends to respond to medicine classes originally developed for epilepsy or depression rather than to ordinary painkillers. Bladder urgency has its own set of medicines and techniques, and a continence specialist is often involved.

Mood and cognition deserve equal attention. Depression is common and treatable, and cognitive changes, such as slower processing or word-finding difficulty, can be assessed and supported with strategies.

Everyday habits matter too. Stopping smoking is associated with slower progression in observational studies. Vitamin D is often checked and corrected if low, though evidence that supplementation alters disease course remains uncertain; the NIH Office of Dietary Supplements summarizes this as unproven. Keeping vaccinations current is generally advised, with timing planned around immune-suppressing treatments by the team.

How serious is demyelinating disease, and how long can you live with it?

These two questions sit behind almost every first consultation, and both deserve straight answers grounded in what studies actually show.

Seriousness varies enormously across the demyelinating family and between individuals with the same diagnosis. Some people have a single episode of optic neuritis, recover, and never have another. Others live with relapsing MS for decades with periods of stability. A minority experience steady progression that affects walking, vision or cognition. NMOSD relapses tend to be more severe than MS relapses, which is why treatment starts earlier. What determines where an individual falls is not fully predictable, though early lesion burden, incomplete recovery from attacks and continued smoking are associated with a harder course.

On life expectancy, the NHS states that average life expectancy for people with MS is around five to ten years lower than average, and that this gap appears to be narrowing. That figure reflects populations diagnosed decades ago, before most current therapies existed, and it is an average that hides wide variation. Most deaths in MS are related to complications of severe disability, such as infections or swallowing difficulties, rather than to the disease process itself, which is one reason attentive long-term care and rehabilitation are considered to influence outcomes.

Mayo Clinic notes that MS most often begins between the ages of 20 and 40 and affects women two to three times as often as men. A diagnosis in early adulthood therefore means planning for a long life alongside the condition, which reframes the goal of treatment: not a finish line, but preserving function over decades.

Honest uncertainty is part of the answer. No clinician can forecast an individual course at diagnosis, and any source that promises a specific outcome is overstating what the evidence supports.

What people often get wrong about demyelinating disease treatment

Myths gather quickly around conditions that are common, variable and hard to explain. A few of the most persistent are worth correcting plainly.

Steroids treat the disease. They treat the relapse. The NHS is explicit that corticosteroids shorten recovery but do not alter the long-term course. Someone who has had three steroid courses in a year has had three relapses treated, not their disease controlled.

If I feel well, the disease is quiet. MRI regularly shows new lesions in people with no new symptoms. This silent activity is a main reason for scheduled scans even when life feels stable.

Disease-modifying therapies will make me feel better. They are preventive, not symptomatic. Some people feel no different on treatment, and a few feel worse from side effects, yet the medicine may still be doing its job. Judging a DMT by how you feel on a Tuesday afternoon is like judging a seatbelt by how comfortable it is.

A special diet can replace medication. Several diets are promoted for demyelinating disease. None has been shown in rigorous trials to reduce relapses or lesions, as Mayo Clinic’s review of complementary approaches notes. A balanced diet supports general health; it is not a substitute for a treatment plan, and it should not be presented as one.

Every flicker of numbness means a new attack. Brief symptoms lasting minutes or hours usually reflect old lesions misfiring, especially with heat, fatigue or infection. The 24-hour threshold exists for this reason.

Demyelination means the nerves are gone. Myelin can be repaired, at least partly, and many people recover substantially from attacks. Lasting disability comes mainly from repeated, cumulative injury, which is exactly what long-term treatment aims to limit.

Questions to ask your care team about treatment and monitoring

Clinic appointments are short and the questions that matter most tend to surface on the drive home. Writing a list beforehand makes the conversation more useful for both sides. These are questions neurologists generally welcome.

• Which demyelinating condition do you think this is, and how confident are you? What tests would change that view?
• Was this most likely a relapse, a pseudo-relapse from infection, or something else, and how did you decide?
• Do you recommend starting a preventive therapy now, or monitoring first? What would make you change that advice?
• For any medicine proposed: how does it work, how long before it is expected to take effect, what side effects should I watch for, and what monitoring does it require?
• How will we judge whether the treatment is working, and what would count as a reason to switch?
• How often will I have MRI scans and blood tests, and who will contact me with the results?
• Who do I call if I develop new symptoms, and how quickly should I expect to be seen?
• How does this plan fit with pregnancy, breastfeeding or future family plans?
• Which vaccinations should I have, and does timing around treatment matter?
• What rehabilitation or symptom support is available, and can I be referred now rather than waiting for problems to build?
• Are there lifestyle changes with reasonable evidence behind them, and which popular claims lack support?

Bring someone with you if you can; a second pair of ears catches what anxiety filters out. Ask for the plan in writing, including the name and mechanism of any medicine discussed. And remember that a good team expects these questions to be asked more than once as circumstances and evidence shift.

When to call your doctor: red-flag signs that should not wait

Most changes in a demyelinating condition are not emergencies, but a few situations need a same-day call to the neurology team or, in some cases, emergency care.

Contact your team promptly if you develop new neurological symptoms lasting more than 24 hours: new weakness, numbness, vision loss or double vision, unsteadiness, or new difficulty with bladder or bowel control. These may represent a relapse that benefits from early assessment. Call as well if existing symptoms worsen sharply, especially alongside fever, burning when passing urine or a cough, since infection can both mimic and trigger relapses and needs treatment in its own right.

Seek emergency care without delay for sudden severe weakness in the legs with loss of bladder or bowel control, rapidly spreading weakness moving up the body, difficulty breathing or swallowing, a severe headache with confusion or drowsiness, seizures, or a high fever with a stiff neck. Sudden loss of vision in one or both eyes should also be assessed urgently.

People taking disease-modifying therapies have additional warning signs linked to their medicine. Report new or persistent fever, unusual infections, unexplained bruising or bleeding, yellowing of the skin or eyes, or a change in thinking, personality, speech or coordination that develops over days to weeks, since the last of these can indicate a rare treatment-related brain infection that needs rapid evaluation. Severe shortness of breath, chest pain or a very slow heartbeat after starting a new medicine also warrant immediate attention.

New or worsening low mood, hopelessness or thoughts of self-harm are medical symptoms too, and they deserve the same speed of response as a physical relapse.

When in doubt, call. Neurology teams would far rather hear about a false alarm than miss a treatable change, and the judgment about what a symptom means belongs to them, not to the person worrying about it at midnight.

Frequently asked questions

Can demyelinating disease be treated or controlled long term?

Yes, most demyelinating diseases can be managed and controlled over the long term, though not reversed entirely. Acute attacks are treated with anti-inflammatory medicines, future relapses are reduced with disease-modifying therapies, and symptoms are addressed through rehabilitation and targeted treatments. Repair of myelin happens naturally to a degree but cannot yet be reliably induced by medicine. The aim of treatment is to preserve function over decades, with the plan tailored by the neurology team.

How long can you live with demyelinating disease?

Many people live for decades with a demyelinating disease. The NHS states that average life expectancy in multiple sclerosis is around five to ten years lower than the general population and that this gap appears to be narrowing. That average reflects people diagnosed before most modern therapies existed and hides wide individual variation. Other demyelinating conditions, such as a single episode of optic neuritis or ADEM, often carry no effect on life expectancy at all.

How serious is demyelinating disease?

Seriousness ranges widely, from a single episode with full recovery to progressive disability, and it cannot be predicted reliably at diagnosis. Multiple sclerosis often involves long stable periods between relapses, while neuromyelitis optica spectrum disorder tends to produce more severe attacks and is treated preventively from the first confirmed episode. Factors associated with a harder course include a high lesion burden on early MRI, incomplete recovery from attacks and continued smoking.

What triggers demyelination and can it be avoided?

No single trigger has been proven. Immune-mediated demyelination arises from a mix of genetic susceptibility, prior infections such as Epstein-Barr virus, low vitamin D, smoking and other factors that raise risk rather than cause disease outright. In someone already diagnosed, infections are associated with a higher chance of relapse in the following weeks. Some demyelination has non-immune causes, including severe vitamin B12 deficiency, which is why a first episode prompts broad blood testing.

What is the difference between a relapse and a pseudo-relapse?

A relapse is new inflammation producing symptoms that last at least 24 hours without fever or infection. A pseudo-relapse is a temporary worsening of existing symptoms caused by something else, most often infection, heat or exhaustion, without new damage. The distinction matters because a pseudo-relapse improves when the trigger is treated and does not need steroids. Clinicians usually check for infection, particularly of the bladder, before treating any suspected relapse.

How long do steroids take to work during a relapse?

Steroids typically begin to reduce inflammation within days, and many people notice early improvement during or shortly after the short course. Full recovery from the relapse, however, continues over weeks or months under the body’s own repair processes, according to the NHS. Steroids speed the early phase rather than change the eventual outcome, so a mild relapse is often left to recover without them to avoid side effects such as sleep disturbance and raised blood sugar.

How often are MRI scans needed for monitoring?

The schedule is set individually by the neurology team rather than by a fixed rule. A baseline scan is usually taken around the time a preventive therapy starts, so later scans can be compared against it, and follow-up scans then look for new or enlarging lesions. Checks are often more frequent early in treatment and spaced out once a therapy appears stable. New symptoms can prompt an additional scan outside the planned rhythm.

Do disease-modifying therapies make you feel better?

Usually not directly. Disease-modifying therapies are preventive: they reduce future relapses and new lesions but do not treat existing symptoms or repair past damage. Some people feel no different on treatment and a few notice side effects, yet the medicine may still be working. Its benefit is judged over years using relapse counts and MRI, not day-to-day wellbeing. Symptoms such as fatigue, stiffness and pain have their own separate treatment pathways.

Can diet or supplements treat demyelinating disease?

No diet or supplement has been shown in rigorous trials to reduce relapses or lesions in demyelinating disease. A balanced diet supports general health, and low vitamin D is often corrected, but the NIH Office of Dietary Supplements describes evidence that supplementation alters disease course as uncertain. Diets promoted as replacements for medication lack supporting trials. Discussing any supplement with the treating team is sensible, since some can interact with prescribed therapies.

What happens if a relapse occurs while on treatment?

A relapse on treatment is treated in the usual way, typically with a short course of corticosteroids if symptoms are disabling, and it becomes information for the team rather than a personal failure. The neurologist will usually review recent MRI findings, consider whether the medicine has had time to reach full effect, and decide whether continuing, switching class or adjusting the monitoring plan is appropriate. That decision rests with the prescribing clinician.

References

• NHS: Multiple sclerosis, Treatment
• NIH NINDS: Multiple Sclerosis
• Cleveland Clinic: Multiple Sclerosis

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.